Mylan Recalls Amlodipine and Benazapril Capsules Due to Cleaning Deviations
Mylan Pharmaceuticals is recalling Amlodipine and Benazapril HCL Capsules because cleaning processes for manufacturing equipment were not followed according to procedure.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, but the source text does not report any illnesses, injuries, or hospitalizations. The hazard is a procedural deviation (cleaning) without reported harm, fitting the 'Moderate' criteria for low-risk contamination or voluntary precautionary recalls.
Plain-English summary
Mylan Pharmaceuticals, Inc. is recalling Amlodipine and Benazapril HCL Capsules, USP, 5 mg/40 mg, 100 count bottles (NDC 0378-6899-01). The recall involves 12,924 bottles with Lot Numbers 3083008 and 3086124, which have an expiration date of January 2019.
The recall was initiated because cleaning processes for the equipment used to manufacture the specified batches were not followed according to procedure, resulting in cGMP deviations. The product was distributed throughout the United States.
Consumers should stop using the recalled product and contact their healthcare provider or pharmacist for guidance on obtaining a replacement.
The recalled product
- Product
- Amlodipine and Benazapril HCL Capsules, USP, 5 mg/40 mg, 100 count bottles, Mylan Pharmaceuticals, Inc., Morgantown, WV --- NDC 0378-6899-01
- Manufacturer
- Mylan Pharmaceuticals Inc.
- Category
- Drug — Prescription Medication
- Affected units
- 12,924
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot Numbers# 3083008 and 3086124
- exp Jan 2019
Distribution
Distribution scope not specified by the agency.
Part of a larger recall action
This product is one of 2 recalled by Mylan Pharmaceuticals Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Mylan Pharmaceuticals Inc.
See all →- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- HighMycophenolate Mofetil Injection Recalled Due to Precipitate in Vials
FDA (Drugs) · 2026-08-05
- HighAmnesteem isotretinoin 40 mg capsules failed dissolution specifications
FDA (Drugs) · 2026-03-11
- HighPrasugrel 5 mg Tablets Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2025-03-26
- CriticalInsulin Glargine Prefilled Pens Recalled for Missing Label
FDA (Drugs) · 2022-08-03
Same hazard · cGMP deviation
See all →- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-07-08
- SevereCinacalcet Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-08
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateIndomethacin Extended-Release Capsules recalled for cGMP deviations
FDA (Drugs) · 2025-06-11
- SevereLubricant Eye Drops Solution recalled due to sterility assurance concerns
FDA (Drugs) · 2025-05-14